Sprouty 3 Inhibitors
Chemical inhibitors of Sprouty 3 can function through various mechanisms to inhibit its activity within the MAPK/ERK signaling pathway. U0126 and PD98059 are both specific inhibitors of MEK1 and MEK2, key kinases in the MAPK/ERK pathway, which Sprouty 3 normally inhibits. By blocking MEK activity, these chemicals reduce the necessity for Sprouty 3's inhibitory action, as the pathway's activation is already diminished. LY294002 and Wortmannin both act as inhibitors of PI3K, a kinase that indirectly regulates the MAPK/ERK pathway. Their action curtails the pathway's activation upstream, therefore, the role of Sprouty 3 in inhibiting this pathway is less crucial. Similarly, SB203580 targets p38 MAPK, and by hindering its activity, it reduces the integrative signaling that may otherwise enhance MAPK/ERK signaling, reducing the need for Sprouty 3's inhibitory function.
In the same vein, SP600125 and PP2 inhibit JNK and Src family kinases, respectively, both of which can modulate the MAPK/ERK pathway. By decreasing the activation signals through these routes, the chemicals lower the functional requirement for Sprouty 3's inhibition of the pathway. Rapamycin inhibits mTOR, part of the PI3K/AKT pathway, which also exercises control over the MAPK/ERK pathway. The inhibition of mTOR by Rapamycin thus limits the downstream signaling that would typically be subject to inhibition by Sprouty 3. SL327, CI-1040, and Dasatinib further contribute to the inhibition of the MAPK/ERK pathway by targeting MEK and various kinases that feed into the pathway, thereby reducing the signaling input that Sprouty 3 would ordinarily restrain. Lastly, Sorafenib acts on RAF kinases, which are precursors in the MAPK/ERK pathway. By inhibiting RAF, Sorafenib lowers the activation of the MAPK/ERK pathway and, as a result, the functional inhibition normally provided by Sprouty 3 is less demanded. Each of these chemicals operates by inhibiting specific kinases or pathways that are intertwined with the MAPK/ERK pathway, thereby minimizing the functional significance of Sprouty 3 as an inhibitor within this signaling cascade.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 selectively inhibits MEK1 and MEK2, which are upstream MAPK/ERK kinase inhibitors. Since Sprouty 3 inhibits the MAPK/ERK pathway, the functional role of Sprouty 3 is reduced by U0126, as it diminishes the need for Sprouty 3's inhibitory action on this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a specific inhibitor of MEK, which works upstream in the MAPK/ERK pathway that Sprouty 3 also functions to inhibit. Inhibition of MEK by PD98059 reduces the signaling that Sprouty 3 would typically inhibit, thereby decreasing Sprouty 3's functional relevance. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, and PI3K signaling is known to interact with the MAPK/ERK pathway. By inhibiting PI3K, LY294002 can reduce the activation of MAPK/ERK signaling, thus indirectly reducing the functional necessity for Sprouty 3 inhibition in this context. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK, another kinase that interacts with the MAPK/ERK pathway. By inhibiting p38 MAPK, SB203580 can decrease the cross-talk activation of ERK, potentially reducing the functional role of Sprouty 3. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which can influence the MAPK/ERK pathway. By inhibiting JNK, SP600125 indirectly reduces the signaling that Sprouty 3 is known to inhibit, thus reducing the functional requirement for Sprouty 3 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor, impairing the PI3K/AKT pathway that can regulate the MAPK/ERK pathway. Through this inhibition, Wortmannin indirectly diminishes the MAPK/ERK signaling cascade, lessening the need for Sprouty 3's inhibitory function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is part of the PI3K/AKT pathway, and can modulate the MAPK/ERK pathway. Inhibition of mTOR by Rapamycin can lead to reduced MAPK/ERK signaling, indirectly reducing the functional role of Sprouty 3. | ||||||
SL-327 | 305350-87-2 | sc-200685 sc-200685A | 1 mg 10 mg | $107.00 $332.00 | 7 | |
SL327 is known to inhibit MEK and therefore reduce ERK phosphorylation, which is a key component of the MAPK/ERK pathway. By inhibiting MEK, SL327 effectively reduces Sprouty 3's inhibitory target signaling. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family kinase inhibitor, and Src kinases can impact the MAPK/ERK pathway. Inhibition of Src kinases by PP2 can decrease activation of components of the MAPK/ERK pathway, thus indirectly decreasing the necessity for Sprouty 3's inhibitory action. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src kinase inhibitor and also inhibits other kinases that can influence the MAPK/ERK pathway. By inhibiting these kinases, Dasatinib indirectly reduces the signaling cascade that Sprouty 3 would inhibit. | ||||||